培美曲塞联合顺铂治疗晚期三阴性乳腺癌的近期疗效

Short-term effect of pemetrexed combined with cisplatin in the treatment for advanced triple-negative breast cancer

目的观察和评价培美曲塞联合顺铂治疗晚期三阴性乳腺癌的近期疗效及不良反应。方法收集2012年1月—2013年1月接受过蒽环类和紫杉类药物化疗失败的晚期三阴性乳腺癌患者43例,给予培美曲塞联合顺铂化疗方案,对其近期疗效及不良反应进行评价。结果 43例患者完全缓解1例,部分缓解10例,稳定18例,进展14例,有效率为25.6%,临床获益率为67.4%;中位疾病进展时间5.9月。主要不良反应为骨髓抑制、皮疹和胃肠道反应。结论培美曲塞联合顺铂治疗晚期三阴性乳腺癌近期疗效较好,不良反应可耐受。

Objective To evaluate the short-term efficacy and side effects of pemetrexed combined with cisplatin in the treatment for advanced triple-negative breast cancer [TNBC]. Methods From Jan 2012 to Jan 2013,43 patients with advanced TNBC who failed in the treatment with anthracycline and taxane received combination of pemetrexed and cisplatin. The short-term efficacy and side effects were evaluated. Results All of 43 patients were evaluable for response with 1case of CR,10 cases of PR,18 cases of SD and 14 cases of PD. The overall response rate was 25.6% and the clinical benefit rate was 67.4%. The median progression-free survival time was 5.9 months. The main side effects were myelosuppression,rash and gastrointestinal reaction which were alleviated by symptomatic treatment. Conclusions Pemetrexed combined with cisplatin regimen is effective with mild toxicity for patients with advanced TNBC after falure in the treatment with anthracycline and taxane.